In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China.
To evaluate the in vitro antimicrobial activities of tedizolid, linezolid and other comparators against clinically significant Gram-positive cocci isolates from hospital-acquired pneumonia (HAP), skin and soft tissue infection (SSTI) and bloodstream infection (BSI), 2140 nonduplicate isolates (23.7 % isolated from HAP, 46.8 % from SSTI and 29.5 % from BSI) were consecutively collected in 26 hospitals in 17 cities across China during 2014. These pathogens included 632 methicillin-resistant Staphylococcus aureus, 867 methicillin-sensitive Staphylococcusaureus, 299 coagulase-negative Staphylococcus (CoNS), 104 Enterococcus faecalis, 99 Enterococcusfaecium, 13 Streptococcus pneumoniae, 23 α-haemolytic Streptococcus and 103 β-haemolytic Streptococcus. MICs of routine clinical antibiotics were determined by broth microdilution method according to the Clinical and Laboratory Standards Institute guidelines 2015. Tedizolid, linezolid, vancomycin, daptomycin, teicoplanin and tigecycline showed high in vitro activity against Gram-positive pathogens (≥98.0 % susceptible), and tedizolid exhibited four- to eight fold greater activity than linezolid against the pathogens tested, with MIC90s of methicillin-resistant Staphylococcus aureus, α-haemolytic Streptococcus and β-haemolytic Streptococcus (0.25 vs 2 µg ml-1); methicillin-sensitive Staphylococcu saureus, E. faecalis and E. faecium (0.5 vs 2 µg ml-1); methicillin-resistant CoNS and methicillin-sensitive CoNS (0.25 vs 1 µg ml-1); and Streptococcuspneumoniae (0.125 vs 0.5 µg ml-1). Tedizolid MIC90s associated with different infections did not show significant differences, and the drug exhibited excellent activity against surveyed Gram-positive pathogens associated with HAP, SSTI and BSI, including linezolid-nonsusceptible strains. These data suggest that tedizolid could be an alternative to linezolid for the treatment of infections caused by Gram-positive organisms.
Department of Clinical Laboratory, Peking University People's Hospital, Beijing 100044, PR China.
Shuguang
S
Li
Department of Clinical Laboratory, Peking University People's Hospital, Beijing 100044, PR China.
Yu
Y
Guo
Department of Clinical Laboratory, Peking University People's Hospital, Beijing 100044, PR China.
Chunjiang
C
Zhao
Department of Clinical Laboratory, Peking University People's Hospital, Beijing 100044, PR China.
Hongbin
H
Chen
Zhongshan Hospital Fudan University, Shanghai 200032, PR China.
Bijie
B
Hu
The First Hospital of China Medical University, Shenyang 110001, PR China.
Yunzhuo
Y
Chu
Shengjing Hospital of China Medical University, Shenyang 110004, PR China.
Zhijie
Z
Zhang
Beijing Hospital, Beijing 100730, PR China.
Yunjian
Y
Hu
Affiliated Xinan Hospital of Third Military Medical University, Chongqing 400038, PR China.
Zhiyong
Z
Liu
First Affiliated Hospital of Kunming Medical University, Kunming 650032, PR China.
Yan
Y
Du
Shanxi Provincial People's Hospital, Xi'an 710068, PR China.
Qiaodi
Q
Gui
The First Teaching Hospital of Xinjiang Medical University, Urumqi 830054, PR China.
Ping
P
Ji
Affiliated Puai Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, PR China.
Ji
J
Zeng
Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, PR China.
Bin
B
Cao
The Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010000, PR China.
Quan
Q
Fu
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, PR China.
Rong
R
Zhang
The First Affiliated Hospital of Anhui Medical University, Hefei 230022, PR China.
Zhongxin
Z
Wang
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, PR China.
Chao
C
Zhuo
The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, PR China.
Xianju
X
Feng
General Hospital of Ningxia Medical University, Yinchuan 750004, PR China.
Wei
W
Jia
Shandong Provincial Hospital, Jinan 250021, PR China.
Yan
Y
Jin
China-Japan Union Hospital of Jilin University, Changchun 130033, PR China.
Xuesong
X
Xu
First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, PR China.
Kang
K
Liao
Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200025, PR China.
Yuxing
Y
Ni
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, PR China.
Yunsong
Y
Yu
Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, PR China.
Xiuli
X
Xu
Tianjin Medical University General Hospital, Tianjin 300052, PR China.
Zhidong
Z
Hu
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China.
Jin-E
JE
Lei
The First Affiliated Hospital, Zhejiang University, Hangzhou 310003, PR China.
Qing
Q
Yang
Department of Clinical Laboratory, Peking University People's Hospital, Beijing 100044, PR China.
Hui
H
Wang
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002681:China; D003428:Cross Infection / Q000382:microbiology; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology; D006761:Hospitals; D006801:Humans; D008826:Microbial Sensitivity Tests; D010755:Organophosphates / Q000494:pharmacology*; D010080:Oxazoles / Q000494:pharmacology*; D018410:Pneumonia, Bacterial / Q000382:microbiology*; D018805:Sepsis / Q000382:microbiology*; D017192:Skin Diseases, Bacterial / Q000382:microbiology*; D018461:Soft Tissue Infections / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D010755:Organophosphates; D010080:Oxazoles; C515040:tedizolid phosphate